Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.185 -0.095 (-1.80%)
Streaming Delayed Price Updated: 10:52 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study ↗
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial... 
Via Benzinga
News headline image
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in Upcoming Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%... 
Via Benzinga
News headline image
Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance ↗
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo... 
Via Benzinga
News headline image
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics (ALDX) Q3 2021 Earnings Call Transcript ↗
ALDX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
News headline image
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics (ALDX) Q2 2021 Earnings Call Transcript ↗
ALDX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate ↗
The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6... 
Via Benzinga
News headline image
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate ↗
The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary... 
Via Benzinga
News headline image
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2... 
Via Benzinga
News headline image
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More ↗
Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive... 
Via Talk Markets
News headline image
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More ↗
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.